• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Rockwell Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    11/13/24 11:41:28 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RMTI alert in real time by email
    false 0001041024 0001041024 2024-11-13 2024-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

     

     

    Date of Report (Date of earliest event reported): November 13, 2024

     

    Rockwell Medical, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware 000-23661 38-3317208
    (State or other jurisdiction
    of incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

    30142 S. Wixom Road, Wixom, Michigan 48393

    (Address of principal executive offices, including zip code)

     

    (248) 960-9009

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
      
    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
      
    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
      
    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class  Trading  Symbol  Name of Each exchange on which
    registered
    Common Stock, par value $0.0001  RMTI  Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 8.01Other Events.

     

    On October 8, 2024, Rockwell Medical, Inc., a Delaware corporation (the “Company”), filed with the U.S. Securities and Exchange Commission (the “SEC”) a shelf registration statement on Form S-3 (the “New Registration Statement”) to replace the existing shelf registration statement on Form S-3 (No. 333-259923) filed with the SEC on September 30, 2021 (the “Prior Registration Statement”), which was scheduled to expire on October 8, 2024, pursuant to Rule 415(a)(5) under the Securities Act of 1933, as amended. The Prior Registration Statement was deemed terminated upon the effectiveness of the New Registration Statement on October 21, 2024.

     

    In connection with the filing of the New Registration Statement, on November 13, 2024, the Company filed a prospectus supplement (the “Prospectus Supplement”) covering the offer and sale of an aggregate offering price of up to $25,000,000 of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), pursuant to the Controlled Equity OfferingSM Sales Agreement, dated April 8, 2022 (the “Sales Agreement”), by and between Cantor Fitzgerald & Co. and the Company. A copy of the Sales Agreement was previously filed as Exhibit 10.2 to the Company’s Annual Report on Form 10-K with the SEC on March 21, 2024.

     

    The Company is filing this Current Report on Form 8-K to provide the legal opinion of its counsel, Gibson, Dunn & Crutcher LLP, regarding the legality of the securities covered by the Prospectus Supplement, which opinion is attached hereto as Exhibit 5.1.

     

    Item 9.01  Financial Statements and Exhibits.
        
    (d)  Exhibits

     

    Exhibit No.   Description
         
    5.1   Opinion of Gibson, Dunn & Crutcher LLP
         
    23.1   Consent of Gibson, Dunn & Crutcher LLP (see Exhibit 5.1)
         
    104   Cover Page Interactive Data File, formatted Inline XBRL and included as Exhibit 101

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ROCKWELL MEDICAL, INC.
         
    Date: November 13, 2024 By:  /s/ Mark Strobeck
        Mark Strobeck
        President and Chief Executive Officer

     

    Get the next $RMTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMTI

    DatePrice TargetRatingAnalyst
    11/14/2024$5.00Buy
    Rodman & Renshaw
    1/18/2022$5.00 → $3.00Buy
    HC Wainwright & Co.
    9/7/2021$5.50 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMTI
    SEC Filings

    View All

    Rockwell Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    3/26/26 7:30:28 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Rockwell Medical Inc.

    10-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    3/26/26 7:01:16 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    3/26/26 6:10:47 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Rockwell Medical with a new price target

    Rodman & Renshaw initiated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00

    11/14/24 7:56:29 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $3.00 from $5.00 previously

    1/18/22 10:00:06 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00 from $5.50 previously

    9/7/21 6:17:47 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rockwell Medical to Release First Quarter 2026 Results on Thursday, May 7, 2026

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET. WEBCAST DETAILS Date: Thursday, May 7, 2026 Time: 8:00am ET Webcast and Replay: www.RockwellMed.com/Results Speakers: Mark Strobeck, Ph.D. — President and Chief Executive Officer Jesse Neri — SVP, Chief Financial Officer Format: Discussi

    4/9/26 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results

    Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. Generated 21% in gross margin for the fourth quarter 2025, representing one of the strongest quarters for gross margin in the Company's history and a meaningful improvement over 15% gross margin for the same period in 2024. Reported $2.3 million in cash flow from operating activities in the fourth quarter 2025, which increased the Company's cash position at year-end 2025 to $25.0 million. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufact

    3/26/26 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical to Release Fourth Quarter and Full-Year 2025 Results on Thursday, March 26, 2026

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2025 on Thursday, March 26, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET. WEBCAST DETAILS Date: Thursday, March 26, 2026 Time: 8:00am ET Webcast and Replay: www.RockwellMed.com/Results Speakers: Mark Strobeck, Ph.D. — President and Chief Executive Officer Jesse Neri — SVP, Chief Financial Off

    2/26/26 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Neri Jesse

    4/A - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    4/17/26 6:52:04 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Timmins Megan C.

    4/A - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    4/17/26 6:51:08 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Chole Timothy

    4/A - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    4/17/26 6:50:07 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Irrevocable Larson Family Investment Trust bought $94,018 worth of shares (87,500 units at $1.07), increasing direct ownership by 3% to 3,557,500 units (SEC Form 4)

    4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    4/15/25 2:02:44 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Leadership Updates

    Live Leadership Updates

    View All

    Rockwell Medical Appoints Joe Dawson to the Company's Board of Directors

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joe Dawson to its board of directors. Additionally, Andrea Heslin Smiley has resigned from the Company's board of directors to pursue other endeavors. "We are pleased to welcome Joe to Rockwell Medical's board of directors. Joe is a seasoned executive who has extensive operational experience, a strong network in the renal care space, and deep domain expertise in building and scaling commercial organizations," said Robert S. Radie, Chairman of t

    11/18/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Names Rashad Brown Vice President, Manufacturing and Supply Chain

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Rashad Brown has joined the Company as Vice President, Manufacturing and Supply Chain. Mr. Brown brings more than two decades of leadership experience in manufacturing operations, procurement, warehouse management, and supply chain optimization within regulated healthcare manufacturing environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111461038/en/Rashad Brown - Vice President, Manufacturing

    11/11/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Universal Display Corporation Announces the Appointment of New Board Members

    Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

    3/7/24 4:05:00 PM ET
    $BDN
    $NOTV
    $OLED
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $RMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rockwell Medical Inc.

    SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    11/14/24 5:17:40 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Rockwell Medical Inc. (Amendment)

    SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    2/14/24 2:31:02 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Rockwell Medical Inc. (Amendment)

    SC 13D/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    9/6/23 4:49:44 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Financials

    Live finance-specific insights

    View All

    Rockwell Medical to Release First Quarter 2026 Results on Thursday, May 7, 2026

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET. WEBCAST DETAILS Date: Thursday, May 7, 2026 Time: 8:00am ET Webcast and Replay: www.RockwellMed.com/Results Speakers: Mark Strobeck, Ph.D. — President and Chief Executive Officer Jesse Neri — SVP, Chief Financial Officer Format: Discussi

    4/9/26 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results

    Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. Generated 21% in gross margin for the fourth quarter 2025, representing one of the strongest quarters for gross margin in the Company's history and a meaningful improvement over 15% gross margin for the same period in 2024. Reported $2.3 million in cash flow from operating activities in the fourth quarter 2025, which increased the Company's cash position at year-end 2025 to $25.0 million. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufact

    3/26/26 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical to Release Fourth Quarter and Full-Year 2025 Results on Thursday, March 26, 2026

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2025 on Thursday, March 26, 2026. The Company will issue a press release at 6:00am ET followed by a live webcast at 8:00am ET. WEBCAST DETAILS Date: Thursday, March 26, 2026 Time: 8:00am ET Webcast and Replay: www.RockwellMed.com/Results Speakers: Mark Strobeck, Ph.D. — President and Chief Executive Officer Jesse Neri — SVP, Chief Financial Off

    2/26/26 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care